By Inflame MariTide, an experimental treatment developed by Amgen, has shown promising results in helping individuals with obesity or Type 2 diabetes achieve significant weight loss. A recent Phase 2 study revealed that non-diabetic participants lost up to 20% of their body weight, while those with diabetes achieved around 17% weight loss over 52 weeks. Importantly, there was no evidence of a weight loss plateau, suggesting further reductions might be possible with continued treatment.
In addition to its weight-loss effects, MariTide improved cardiometabolic health markers such as blood pressure, triglycerides, and inflammation levels (hs-CRP). No significant changes were observed in bone mineral density or free fatty acid levels, further supporting its safety profile.
The study highlighted that gastrointestinal (GI) issues like nausea, vomiting, and constipation were the most common side effects. These symptoms were typically mild, short-lived, and often occurred with the first dose. Gradual dose escalation significantly reduced the occurrence of side effects, and most resolved within a few days. Despite this, about 11% of participants in the dose escalation group discontinued due to side effects, with less than 8% doing so for GI-related reasons.
MariTide is administered via a convenient, single monthly injection using a handheld device. This innovative treatment combines two mechanisms: activating GLP-1 receptors to enhance weight loss and inhibiting GIP receptors to reduce the chances of regaining weight after stopping the medication.
Dr. Jay Bradner, Amgen’s chief scientific officer, expressed enthusiasm about MariTide’s performance, stating, “Its combination of progressive weight loss, improved metabolic health, and monthly dosing offers a unique option for managing obesity and related conditions.”
About the Study:
The Phase 2 trial involved 592 adults with obesity or overweight, divided into two groups: one without Type 2 diabetes and the other with diabetes. Participants received varying doses of MariTide or a placebo. By week 52, those who achieved at least 15% weight loss could continue into Part 2 of the study to evaluate sustained weight loss, maintenance with lower doses, and durability after stopping treatment.
The next steps involve a larger Phase 3 trial, named MARITIME, to test MariTide’s effectiveness across a broader range of patients. With its potential for significant and sustainable weight loss, MariTide could become a groundbreaking option for managing obesity and Type 2 diabetes.